Neumora Therapeutics
Neumora Therapeutics is a biotech company focused on developing precision medicines for brain diseases, with a pipeline that includes seven programs targeting CNS disorders.
Company Overview
Neumora Therapeutics is dedicated to pioneering a new era of medicines for brain diseases. The company focuses on developing precision medicines for neurological disorders using the latest scientific and technological advancements. The aim is to address the global brain disease crisis, which affects over 1.5 billion people worldwide.
Therapeutic Pipeline
Neumora Therapeutics' pipeline includes seven programs centered on neuropsychiatric disorders and neurodegenerative diseases. These programs target novel mechanisms of action within the central nervous system (CNS). The lead program, navacaprant, is a kappa opioid receptor antagonist currently in Phase 3 for major depressive disorder (MDD).
Precision Toolbox
Neumora Therapeutics employs a Precision Toolbox designed to integrate translational, clinical, and computational tools. This comprehensive approach enables the development of targeted therapies for brain diseases, aiming to deliver precise and effective treatments.
Locations
Operating in key biotechnology hubs, Neumora Therapeutics has locations in the Greater Boston area and South San Francisco. These strategic sites allow the company to collaborate with leading scientific and medical communities.